Cytosorbents Corporation
CTSO
$0.59
$0.000.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.50M | -3.17M | 1.95M | -1.48M | -7.57M |
| Total Depreciation and Amortization | 385.00K | 401.00K | 440.30K | 404.70K | 425.00K |
| Total Amortization of Deferred Charges | 249.00K | 190.00K | 190.60K | 190.40K | 191.00K |
| Total Other Non-Cash Items | 1.20M | 736.00K | -5.35M | -2.19M | 5.85M |
| Change in Net Operating Assets | -1.17M | -734.00K | 1.26M | -388.00K | -1.24M |
| Cash from Operations | -4.83M | -2.58M | -1.51M | -3.47M | -2.34M |
| Capital Expenditure | -108.00K | -17.00K | -36.90K | -2.10K | -69.00K |
| Sale of Property, Plant, and Equipment | 76.00K | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -259.00K | 72.00K | -94.90K | -45.10K | -55.00K |
| Cash from Investing | -291.00K | 55.00K | -131.80K | -47.20K | -124.00K |
| Total Debt Issued | 2.48M | -- | -- | -- | 0.00 |
| Total Debt Repaid | -- | -- | -- | -- | 0.00 |
| Issuance of Common Stock | 0.00 | 0.00 | -- | 6.83M | 167.00K |
| Repurchase of Common Stock | -- | -- | -1.10K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 0.00 |
| Cash from Financing | 2.48M | 0.00 | -1.10K | 6.83M | 167.00K |
| Foreign Exchange rate Adjustments | 1.35M | -146.00K | 259.10K | 25.90K | -106.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.29M | -2.67M | -1.38M | 3.35M | -2.40M |